Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

Royal Marsden London: Study shows prediction power of CT-based 2D and 3D texture analysis for liver metastases

2 minute(s)

In a retrospective study [1], a team from Royal Marsden in London and Sutton explored changes of CT texture analysis metrics in unresectable liver…

The Mint Experience of Dr. Stephen Raskin, Sheba Medical Center in Tel Aviv

From my initial experience with mint Lesion™ software, and over the time I have been using it, I have been pleased with the software and come to…

How mint Lesion 3.5 helps you to benefit from Artificial Intelligence in Radiology

According to researchers, every adult makes 35,000 decisions each day. While there are no numbers in literature about how many decisions a radiologist…